ACCESSWIRE
16 Aug 2022, 22:37 GMT+10
TORONTO, ON / ACCESSWIRE / August 16, 2022 / StageZero Life Sciences ('StageZero' or the 'Company') (TSX:SZLS) (OTCQB:SZLSF), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its second quarter financial results for the three months ended June 30, 2022, and provided an update on its business progress.
Operational Updates and Recent Highlights
Q2 continued the transition from COVID to cancer testing. In the first six months of 2022, we:
Continuing through the next twelve months, the Company's focus will be to:
'When the pandemic began in early 2020, we pivoted to offer COVID testing solutions to individuals and employers. It built our business, introduced us to new partners and allowed us time to acquire and build out the key support systems employers had asked for in cancer screening and wellness programs. As the pandemic recedes, employers are returning to focus on driving their businesses and that includes employee welfare and corporate healthcare cost reduction. We are, again, working with employers in testing for cancer but, this time we have the ability to meet all of their needs and provide the follow up' said James Howard-Tripp, Chairman and CEO of StageZero, 'We are unique in our ability to offer both the testing options and then provide follow up when needed'.
Q2 2022 Financial Results
All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.
The Company generated $2.3 million in revenue for the six months ended June 30, 2022 as compared to $2.9 million in revenue for the six months ended June 30, 2021and realized a net loss of $1.9 million, or $0.02 basic and diluted loss per common share as compared to a $3.0 million net loss for the six months ended June 30, 2021, or $0.03 basic and diluted loss per common share. Adjusted EBITDA for the six months ended June 30, 2022 totaled ($4.60 million).
The Company generated $1.0 million in revenue for the three months ended June 30, 2022 as compared to $0.4 million in revenue for the three months ended June 30, 2021 and realized a net loss of $1.3 million, or $0.01 basic and diluted loss per common share as compared to a $4.3 million net income (affected by the revaluation of warrant liability) for the three months ended June 30, 2021, or $0.05 basic and diluted income per common share. Adjusted EBITDA for the three months ended June 30, 2022 totaled ($2.0 million).
EBITDA and Adjusted EBITDA
Earnings before interest, taxes, depreciation and amortization ('EBITDA') and adjusted earnings before interest, taxes, depreciation and amortization ('Adjusted EBITDA') are not recognized performance measures under IFRS. EBITDA and Adjusted EBITDA do not have standardized meanings under IFRS and therefore may not be comparable to similar measures presented by other issuers. The term EBITDA consists of net income (loss) and excludes interest, finance costs, taxes, depreciation and amortization. Adjusted EBITDA also excludes share-based compensation, impairment of assets, revaluation of warrants, changes in fair value of conversion debenture and public entity costs. EBITDA and Adjusted EBITDA are included as supplemental disclosures because Management believes that these disclosures provide a better assessment of the Company's continuing operations by eliminating non-cash costs and costs or gains that are not recurring.
The Company's financial statements and management's discussion and analysis are available on www.sedar.com.
Analyst and Investor Call
Event Date: Tuesday August 16, 2022
Time: 8:30 a.m. EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/46389
Participant Numbers:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 811487
Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 46389
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as 'expects', 'will' and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences Ltd.
Get a daily dose of Chicago Chronicle news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Chicago Chronicle.
More InformationBEIJING, China: The Chaoyang District Intermediary Court in Beijing has begun compensation hearings for the Chinese relatives of those who ...
Israel resumed its military operation in the Gaza Strip on Friday with heavy bombardments. As strikes continue, the United States ...
LIVINGSTON, Kentucky: CSX railroad said that a failed wheel bearing on a train car caused a derailment on November 22 ...
HELSINKI, Finland: After Finland joined the North Atlantic Treaty Organization (NATO) earlier this year, hundreds of migrants from the Middle ...
CHISINAU, Moldova: Over the weekend, heavy snowfall and strong blizzards in Romania, Moldova and Bulgaria left one person dead and ...
WASHINGTON D.C.: After a House Ethics Committee report found substantial evidence that he broke the law, New York Republican representative ...
This campaign explores ice hockey players' influence and popularity beyond their National Hockey League (NHL) careers. The goal was to ...
(Photo credit: Christopher Hanewinckel-USA TODAY Sports) The Minnesota Wild will look to stay unbeaten since their coaching change when they ...
Chicago [US], December 3 (ANI): According to a study presented at the annual meeting of the Radiological Society of North ...
indianapolis - A federal jury in Illinois ordered $17.7 million in damages - an amount tripled to more than $53 ...
(Photo credit: Jordan Prather-USA TODAY Sports) Trazarien White scored 27 points and had 10 rebounds off the bench, and UNC ...
(Photo credit: Dan Hamilton-USA TODAY Sports) Brad Marchand scored at 4:52 of overtime and the visiting Boston Bruins recovered from ...